Skip Navigation

European Heart Journal 2002 23(14):1087-1092; doi:10.1053/euhj.2001.3037
Copyright © 2002 by the European Society of Cardiology.
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (17)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by White, H.L.
Right arrow Articles by Balmforth, A.J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by White, H.L.
Right arrow Articles by Balmforth, A.J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

An evaluation of the beta-1 adrenergic receptor Arg389Gly polymorphism in individuals at risk of coronary events. A WOSCOPS substudy

H.L. Whitea,f1, A. Maqboola, A.D. McMahonb, L. Yatesa, S.G. Balla, A.S. Halla and A.J. Balmfortha

a Institute for Cardiovascular Research, University of Leeds, U.K.
b Robertson Centre for Biostatistics, University of Glasgow, U.K.

revised September 18, 2001; accepted September 21, 2001

Abstract

Aims The Glycine389 variant of the beta-1 adrenergic receptor generates markedly less cAMP when stimulated in vitro than the more prevalent Arginine389 variant and may confer protection against coronary events similar to that observed with beta-blockers. The aim of this study was to ascertain whether this Glycine389 variant protects against coronary events.

Methods and Results We identified the genotype at position 389 of the ß1AR in 1554 individuals taken from men enrolled in the West of Scotland Coronary Prevention Study. Men with a coronary event (event group) were each matched for age and smoking status with two control subjects from the same cohort who had not had a coronary event (control group). We compared the distribution of genotypes in the event and control groups. Conditional logistic regression was used to calculate odds ratios for each of the genotypes. The prevalence of the three genotypes in the entire cohort was ArgArg 53.5%, ArgGly 39.6%, GlyGly 6.9%. The Arg389Gly beta-1 adrenergic receptor polymorphism was not associated with coronary events. Using the ArgArg genotype as the reference, the odds ratio for the ArgGly genotype was 1·1 (95% CI, 0·88–1·38) and for the GlyGly genotype it was 1·05 (95% CI, 0·68–1·62).

Conclusion Our longitudinal case-control study demonstrates that the Glycine389 variant of the beta-1 adrenergic receptor does not protect against coronary events. Copyright 2002 The European Society of Cardiology. Published by Elsevier Science Ltd. All rights reserved.

Key Words: Beta-1 adrenergic receptor, polymorphism, myocardial infarction

f1 Correspondence: Hazel L. White, Institute for Cardiovascular Research, University of Leeds, U.K.

References

  1. Cruickshank JM. ß-blockers: primary and secondary prevention. J Cardiovasc Pharmacol. 1992;20:S55–S69
  2. Brodde O, Michael MC. Adrenergic and muscarinic receptors in the human heart. Pharmacol Rev. 1999;51:651–689[Abstract/Free Full Text]
  3. Mason DA, Moore JD, Green SA. A gain of function polymorphism in a G-protein coupling domain of the human beta 1 adrenergic receptor. J Biol Chem. 1999;274:12670–12674[Abstract/Free Full Text]
  4. Cody RJ. The sympathetic nervous system and the renin-angiotensin-aldosterone system in cardiovascular disease. Am J Cardiol. 1997;80:9J–14J[CrossRef][Medline]
  5. Kannel WB, Kannel C, Paffenbarger RS, Cupples LA. Heart rate and cardiovascular mortality: the Framingham Study. Am Heart J. 1987;113:1489–1494[CrossRef][ISI][Medline]
  6. Coehlo R, Ramos E, Prata J. Acute myocardial infarction: psychosocial and cardiovascular risk factors in men. J Cardiovasc Risk. 1999;6:157–162[ISI][Medline]
  7. Petterson K, Bejne B, Bjork H. Experimental sympathetic activation causes endothelial injury in the rabbit thoracic aorta via ß1-adrenoceptor activation. Circ Res. 1990;67:1027–1034[Abstract/Free Full Text]
  8. Shah PK. Plaque disruption and coronary thrombosis: new insight into pathogenesis and prevention. Clin Cardiol. 1997;20:II-38–44
  9. Johnstone MT, Mittleman M, Tofler G. The pathophysiology of the onset of morning cardiovascular events. Am J Hypertens. 1996;9:22S–28S[Medline]
  10. Tofler GH, Stone PH, Maclure M. Analysis of possible triggers of acute myocardial infarction (the MILIS study). Am J Cardiol. 1990;66:22–27[CrossRef][ISI][Medline]
  11. Wikstrand J, Berglund G, Tuomilehto J. Beta blockade in the primary prevention of coronary artery disease in hypertensive patients. Review of present evidence. Circulation. 1991;84:V193–200
  12. Shepherd J, Cobbe SM, Ford I. Prevention of coronary heart disease with pravastatin in men with hypercholesterolaemia. N Engl J Med. 1995;333:1301–1307[Abstract/Free Full Text]
  13. Maqbool A, Hall AS, Ball SG. Common polymorphisms of the beta 1-adrenoceptor: identification and rapid screening assay. Lancet. 1999;353:897[ISI][Medline]
  14. O'Shaughessy KM, Fu B, Dickerson C. The gain of function G389R variant of the ß1-adrenoceptor does not influence blood pressure or heart rate response to ß-blockade in hypertensive subjects. Clin Sci. 2000;99:233–238[Medline]
  15. Buscher R, Belger H, Eilmes KJ. In-vivo studies do not support a major functional role for the Gly389Arg ß1-adrenoceptor polymorphism in humans. Pharmacogenetics. 2001;11:199–205[CrossRef][ISI][Medline]
  16. Xie H-G, Dishy V, Sofowora G. Arg389Gly ß1-adrenoceptor polymorphism varies in frequency among different ethnic groups but does not alter response in vivo. Pharmacogenetics. 2001;11:191–197[CrossRef][ISI][Medline]
  17. Haass M, Kubler W. Nicotine and sympathetic neurotransmission. Cardiovasc Drugs Ther. 1997;10:657–665[CrossRef][ISI][Medline]
  18. Tuomilehto J, Wikstrand J, Olsson G. Decreased coronary heart disease in hypertensive smokers: Mortality results from the MAPHY study. Hypertension. 1989;13:773–780[Abstract/Free Full Text]
  19. Rathz DA, Liggett SB. Hierarchy of genotype and desensitisation permutations on ß1-adrenergic receptor signalling (Abstr). Circulation. 2000;102:II-102–485
  20. Yu S-M, Tsai S-Y, Guh J-H. Mechanism of catecholamine-induced proliferation of vascular smooth muscle cells. Circulation. 1996;94:547–554[Abstract/Free Full Text]
  21. Anfossi G, Travoti M. Role of catecholamines in platelet function: pathophysiological significance. Eur J Clin Invest. 1996;26:353–370[CrossRef][ISI][Medline]
  22. Izeboud CA, Mocking JA, Monshouwer M. Participation of beta-adrenergic receptors on macrophages in modulation of LPS-induced cytokine release. J Rec Sig Transduct Res. 1999;19:191–202
  23. Small KM, Forbes SL, Rahman FF. A four amino acid deletion polymorphism in the third intracellular loop of the human alpha 2c-adrenergic receptor confers impaired coupling to multiple effectors. J Biol Chem. 2000;275:23059–23064[Abstract/Free Full Text]
  24. McGraw DW, Liggett SB. Coding block and 5 leader cistron polymorphisms of the beta2-adrenergic receptor. Clin Exp Allergy. 1999;29:43–45
  25. British Heart Foundation, Coronary Heart Disease Statistics 1998
  26. Bristow MR. ß-adrenergic receptor blockade in chronic heart failure. Circulation. 2000;101:558–569[Free Full Text]
  27. Borjesson M, Magnusson Y, Hjalmarson A. A novel polymorphism in the gene coding for the beta 1-adrenergic receptor associated with survival in patients with heart failure. Eur Heart J. 2000;21:1853–1858[Abstract/Free Full Text]
  28. Tesson F, Charron P, Peuchmaurd M. Characterisation of a unique genetic variant in the ß1-adrenoceptor gene and evaluation of its role in idiopathic dilated cardiomyopathy. J Mol Cell Cardiol. 1999;31:1025–1032[CrossRef][ISI][Medline]

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Eur Heart JHome page
S. Amisten, O. Melander, A.-K. Wihlborg, G. Berglund, and D. Erlinge
Increased risk of acute myocardial infarction and elevated levels of C-reactive protein in carriersof the Thr-87 variant of the ATP receptor P2Y11
Eur. Heart J., January 1, 2007; 28(1): 13 - 18.
[Abstract] [Full Text] [PDF]

Home page
 Pharmacol. Rev.Home page
S. L. Kirstein and P. A. Insel
Autonomic Nervous System Pharmacogenomics: A Progress Report
Pharmacol. Rev., March 1, 2004; 56(1): 31 - 52.
[Abstract] [Full Text] [PDF]

Home page
 Circ. Res.Home page
M. J. Lohse, S. Engelhardt, and T. Eschenhagen
What Is the Role of {beta}-Adrenergic Signaling in Heart Failure?
Circ. Res., November 14, 2003; 93(10): 896 - 906.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart JHome page
A. Jones and H. Montgomery
The Gly389Arg beta-1 adrenoceptor polymorphism and cardiovascular disease: time for a rethink in the funding of genetic studies?
Eur. Heart J., July 2, 2002; 23(14): 1071 - 1074.
[Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (17)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by White, H.L.
Right arrow Articles by Balmforth, A.J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by White, H.L.
Right arrow Articles by Balmforth, A.J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?